CXCL12 and hepatocellular carcinoma: Accordingly, Chen et al. showed that CXCR4/CXCL12 blockade synergized with anti-PD-L1 immunotherapy in advanced hepatocellular carcinoma (82), while a similar mechanism was recently reported in an in vivo model of colorectal cancer (83).